AstraZeneca announces that Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult patients with unresectable or recurrent (HR) HER2-positive or HER2-negative breast cancer after progression following endocrine therapy.

The approval by Japan's Ministry of Health, Labor and Welfare (MHLW) was based on the results of a phase III trial published in the New England Journal of Medicine.

' Breast cancer is the most common cancer among women in Japan, and innovative new treatment options are urgently needed. Today's approval of Truqap [...] represents a significant step forward', commented Dave Fredrickson, Executive Vice President of AstraZeneca's Oncology Business Unit.

Copyright (c) 2024 CercleFinance.com. All rights reserved.